- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
- TransCode Therapeutics Reports 2023 Results; Provides Business Update
- TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
- TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
- TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
- TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
- Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
- TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
- TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
- TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
More ▼
Key statistics
On Friday, Transcode Therapeutics Inc (RNAZ:NAQ) closed at 0.82, 95.24% above the 52 week low of 0.42 set on Apr 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.75 |
---|---|
High | 1.05 |
Low | 0.695 |
Bid | 0.7853 |
Offer | 0.8401 |
Previous close | 0.707 |
Average volume | 1.26m |
---|---|
Shares outstanding | 5.81m |
Free float | 5.80m |
P/E (TTM) | -- |
Market cap | 4.76m USD |
EPS (TTM) | -473.31 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼